Evidence library

The clinical, economic and church sources behind One Body’s asks, including the evidence that cuts the other way.

Evidence that supports the Medical Trust’s decision is here too. General information, not medical advice.

The Medical Trust’s own documents

  • 2027 Annual Enrollment Guide (October 2026): the exclusion, the 13.3% average increase, and “22.5% absent any action.” PDF
  • 2027 plan design webinar for administrators (August 13, 2026): $8.9 million and 3.6 percentage points saved; “no grandfathering”; a premium plan with GLP-1 coverage considered and rejected; net cost after rebates “twice” the direct-to-consumer price. See the slides and the recording.
  • Denominational Health Plan 2025 Annual Report (July 2026): EncircleRx “estimated to have generated $3.2 million in savings in 2025”; cost trend down “from 148% in 2024 to 62% in 2025”; net losses of $19.4 million (2025) and $10.7 million (2024); median member age 51. PDF
  • CPG Connect, “Navigating a Difficult Healthcare Landscape” (September 14, 2026): spending of $1.5 million (2023) and $7.2 million (2025). Article
  • Episcopal News Service (September 24, 2026): “Episcopal employee insurance rates rising as much as 14% in 2027.” Article

What these medicines do

  • Heart attacks, strokes and cardiovascular death: down 20% with semaglutide in adults with heart disease and overweight or obesity, without diabetes (hazard ratio 0.80, 95% CI 0.72–0.90). Lincoff AM et al., SELECT, NEJM 2023;389:2221–2232. doi:10.1056/NEJMoa2307563

  • Weight:

  • Heart failure with preserved ejection fraction: better symptoms and function with both drugs. Kosiborod MN et al., STEP-HFpEF, NEJM 2023. doi:10.1056/NEJMoa2306963. Packer M et al., SUMMIT, NEJM 2025. doi:10.1056/NEJMoa2410027

  • Diabetes prevention: among people with prediabetes, 1.3% on tirzepatide versus 13.3% on placebo developed type 2 diabetes over about three years. Jastreboff AM et al., NEJM 2025;392:958–971. doi:10.1056/NEJMoa2410819

  • FDA-approved uses as of October 2026:

    • Wegovy: chronic weight management; reducing major cardiovascular events in established heart disease; noncirrhotic MASH with moderate-to-advanced fibrosis.
    • Zepbound: chronic weight management; moderate-to-severe obstructive sleep apnea with obesity.

    Sources: the Wegovy label and the Zepbound label.

What happens when people stop

  • Semaglutide: about two-thirds of lost weight regained within a year of stopping, and cardiometabolic improvements largely reversed. Wilding JPH et al., STEP 1 extension, Diabetes Obes Metab 2022. doi:10.1111/dom.14725
  • Tirzepatide: people switched to placebo regained 14% of body weight over a year, while those who continued lost a further 5.5%. Aronne LJ et al., SURMOUNT-4, JAMA 2024. doi:10.1001/jama.2023.24945
  • Across 37 studies: weight projected back to baseline in about 1.7 years and cardiometabolic markers in about 1.4 years after stopping. West S et al., BMJ 2026;392:e085304. doi:10.1136/bmj-2025-085304
  • The American Diabetes Association’s 2026 obesity standards advise continuing medication after goals are met, because stopping “often results in weight recurrence and worsening or reemergence of cardiometabolic risk factors.” doi:10.2337/doci25-0008

Cost and value

  • Cost-effective at current net prices. ICER found semaglutide and tirzepatide cost-effective at the $100,000-per-QALY threshold at net prices of about $6,800–$8,000 a year. Its independent panel judged their long-term value “high.” It also warned about affordability. It urged steep price cuts, and said payers that narrow coverage for a time should widen it as prices fall and avoid “onerous clinical eligibility criteria.” See the ICER Report at a Glance, December 2025 and the ICER policy recommendations.

  • Prices are falling. Manufacturer self-pay prices in October 2026: Wegovy pens $349 per 28-day box, Wegovy pills from $149, Zepbound $299–$449. Under the November 2025 agreements, Medicare pays $245 a month.

  • Managed coverage can show medical savings. Connecticut’s state employee plan requires a weight-management program. An independent evaluation found about $101–$105 per participant per month in medical savings, with medical cost growth of 12.3% versus 26.1%. The evaluation notes that drug costs rose and that participants chose to enroll. (Segal evaluation, March 2026)

  • Evidence on the other side:

    These are reasons to manage the benefit carefully. Some long-term savings also accrue to a churchwide plan that keeps clergy as they move between parishes.

What other plans do

Plan Weight-loss GLP-1 coverage
Presbyterian Church (U.S.A.) Board of Pensions Covered with prior authorization and a required weight-management program (Express Scripts and Teladoc). Board of Pensions
ELCA (Portico Benefit Services) Ended for weight loss (announced April 2025). Southwestern Pennsylvania Synod
United Church of Christ (Pension Boards) Listed “Anti-obesity medications” as not covered in its 2025 plan summary. 2025 plan highlights (archived copy)
United Methodist Church (Wespath HealthFlex) The 2027 drug list includes Wegovy and Zepbound with prior authorization, and says coverage “is determined by your prescription medication benefit plan.” 2027 drug list
Unitarian Universalist plan Ended December 31, 2025, “hopes that the price will drop sufficiently to restore access.” UUA Health Plan letter
Delaware state employees Kept with a $200 monthly copay (2026). WTW for the Delaware plan
Massachusetts state employees Ended for weight loss only; kept heart-risk, sleep apnea and MASH uses (2026). GBH News
Colorado state employees Ended for new users in 2025 but kept current users at a higher copay; restored for all members May 1, 2026 ($120 copay). Colorado’s FAQ
Ohio state employees Ended July 1, 2025, letting existing approvals run until they expired; from October 7, 2025, a program with Virta paid back $200 a month toward direct purchases, for up to 2,500 employees. WTW and Ohio’s announcement
Connecticut state employees Kept with a required program. Connecticut Comptroller
Federal employees (FEHB), 2027 Plans must cover at least one GLP-1 for obesity, with behavioral therapy. OPM call letter
Washington University in St. Louis Contributes up to $350 a month toward members’ direct purchases. Program page

Large employers: 33% of firms with 5,000 or more workers covered GLP-1s for weight loss in 2026, down from 43% in 2025 (KFF Employer Health Benefits Survey, 2026). Coverage is shrinking, but managed coverage remains common among the largest employers.

Clergy health

  • Higher obesity among clergy: about 47% in 2021, about ten points above US workers (95% CI 8.1–11.4 points). Eagle D et al., Obesity Reviews 2024. doi:10.1111/obr.13741
  • Higher rates of obesity and chronic disease among United Methodist clergy in North Carolina than among their neighbors. Proeschold-Bell RJ, LeGrand S, Obesity 2010. doi:10.1038/oby.2010.102
  • Higher blood-pressure, blood-sugar and cholesterol risk among Episcopal clergy than a benchmark population, with stress a risk factor for 73%. CPG/CREDO, Episcopal Clergy Wellness (2006). PDF

Church decisions on the health plan

  • Resolution 2009-A177 created the Denominational Health Plan and parity between clergy and lay employees. CPG’s page on the resolution
  • Resolution 2024-A101 urges CPG to offer benefits “comparable to those offered by the benefit agencies of similar denominations” (ELCA, UMC, PC(USA), UCC), and to develop pricing “in consultation with the CPG Client Council, the House of Bishops, and other pertinent stakeholders.” It also urges CPG “to continue collaborating with them when feasible for achieving greater purchasing power in the provision of prescription drug benefit offerings,” and to make the plans “self-sufficient and self-funding at each offered benefit level to the extent possible and appropriate.” Virtual Binder and Acts of Convention
  • The Medical Trust buys its pharmacy benefits through a purchasing group of church plans, the Church Benefits Association. In August 2023 it wrote that “Express Scripts will remain our PBM through 2026,” so a new term begins in 2027. 2024 renewal letter, posted by the Diocese of Louisiana
  • Resolution 1985-A083 said of alcohol and drug dependence: “Church health insurance policies should include provision for the treatment and care of persons afflicted with these illnesses.” Acts of Convention
  • Resolution 2015-A159 names “the disease of addiction” and says the Church has “a moral and ethical responsibility” to advocate for “health insurance coverage for prevention, intervention, treatment and recovery.” Acts of Convention
  • Resolution 2012-B026 asks the Medical Trust to “make an annual written report to the Executive Council, the House of Bishops” and its own boards. Acts of Convention
  • Resolution 2022-C065 “strongly recommends the Church Pension Group make available adequate 12-week coverage” for maternity disability. CPG offered a product effective January 1, 2023. Archives research report

Last updated

Back to top